En español

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

This study, building on the lessons learned from the ADAPT Study; will further investigate the effectiveness and safety of a combination pharmacotherapy (XR-NTX; as Vivitrol® plus once-daily bupropion extended-release tablets) for methamphetamine use disorder. 

CTN Protocol ID: 
Enrollment Status: 
Principal Investigator(s)
Madhukar H. Trivedi, M.D.
University of Texas Southwestern Medical Center
Mood Disorders Research Program and Clinic
5325 Harry Hines Blvd, MC9119
Dallas, TX 75390

Get this Publication

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.